+

WO1992004892A1 - Use of nabumetone against calcium depletion - Google Patents

Use of nabumetone against calcium depletion Download PDF

Info

Publication number
WO1992004892A1
WO1992004892A1 PCT/EP1991/001750 EP9101750W WO9204892A1 WO 1992004892 A1 WO1992004892 A1 WO 1992004892A1 EP 9101750 W EP9101750 W EP 9101750W WO 9204892 A1 WO9204892 A1 WO 9204892A1
Authority
WO
WIPO (PCT)
Prior art keywords
nabumetone
treatment
prophylaxis
pharmaceutical composition
calcium depletion
Prior art date
Application number
PCT/EP1991/001750
Other languages
French (fr)
Inventor
Enzo Grossi
Original Assignee
Dr. Lo. Zambeletti S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Lo. Zambeletti S.P.A. filed Critical Dr. Lo. Zambeletti S.P.A.
Publication of WO1992004892A1 publication Critical patent/WO1992004892A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Definitions

  • the present invention relates to a method for the treatment of disorders associated with calcium depletion in the bone and to a compound for use in such a method.
  • Patent 1,474,377 discloses the compound 4-(6'- methoxy-2'-na ⁇ hthyl)-butan-2-one and in example 5, a process by which it can be prepared.
  • the compound which is referred to herein by its common name, nabumetone, is described as possessing anti-inflammatory activity and is therefore useful in the treatment of arthritis.
  • nabumetone also has potential therapeutic utility as a calcium reabsorption agent.
  • the present invention provides a method for the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone in human or non-human animals, which method comprises administering an effective, non-toxic amount of nabumetone to human or non-human animals suffering from such a disorder.
  • the present invention also provides the use of nabumetone in the manufacture of a medicament for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone.
  • a nabumetone medicament for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone may be prepared by admixture of nabumetone with an appropriate carrier, which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • an appropriate carrier which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.
  • disorders associated with calcium depletion in the bone include osteoporosis, ricketts and calcium depletion in females associated with pregnancy.
  • the medicament is in unit dosage form and in a form adapted for use in the medical or veterinarial fields.
  • preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of calcium depletion in bone.
  • the suitable dosage range for nabumetone depends on the nature of the calcium depletion and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
  • Nabumetone may be formulated for administration by any route, and examples are oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of nabumetone.
  • the medicaments may, for example, be in the form of tablets, dispersible tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • the medicaments may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example starch, polyvinylpyrrolidon
  • Solid medicaments may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute nabumetone throughout those medicaments employing large quantities of fillers.
  • any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the medicament may also be in the form of an ingestible capsule, for example of gelatin containing nabumetone if desired with a carrier or other excipients.
  • Medicaments for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid medicaments may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring
  • Nabumetone may also be administered by a non-oral route.
  • the medicaments may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids.
  • the liquid may contain bacteriostatic agents, an i-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives.
  • Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
  • the effective dose of nabumetone depends on the nature of the calcium depletion in the bone, the condition of the patient and on the frequency and route of administration.
  • a unit dose will generally contain from 20 to 2000 mg of nabumetone and preferably will contain from 30 to 1000 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 750, 800 or 1000 mg.
  • the composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg.
  • the unit dose will contain from 2 to 20 mg of nabumetone and be administered in multiples, if desired, to give the preceding daily dose.
  • nabumetone compositions are in the form of 500 mg swallow tablets.
  • the present invention further provides a pharmaceutical composition for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier.
  • Such compositions may be prepared in the manner as hereinbefore described.
  • the average reduction was 31.8%: from 25.7 mg/ml/hr. to 17.5 mg/ml/hr. (P ⁇ 0.05).
  • nabumetone may be able to reduce the amount of bone resorption in patents with IH and may have a prophylactic role in hypercalciuric patients with high bone turnover who are candidates for developing osteoporosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of nabumetone in the manufacture of a medicament for the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone.

Description

Use of nabumetone against calcium depletion
The present invention relates to a method for the treatment of disorders associated with calcium depletion in the bone and to a compound for use in such a method.
G.B. Patent 1,474,377 discloses the compound 4-(6'- methoxy-2'-naρhthyl)-butan-2-one and in example 5, a process by which it can be prepared. The compound which is referred to herein by its common name, nabumetone, is described as possessing anti-inflammatory activity and is therefore useful in the treatment of arthritis.
It has now been surprisingly found that nabumetone also has potential therapeutic utility as a calcium reabsorption agent.
Accordingly, the present invention provides a method for the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone in human or non-human animals, which method comprises administering an effective, non-toxic amount of nabumetone to human or non-human animals suffering from such a disorder.
The present invention also provides the use of nabumetone in the manufacture of a medicament for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone.
A nabumetone medicament, for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone may be prepared by admixture of nabumetone with an appropriate carrier, which may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner. Examples of disorders associated with calcium depletion in the bone include osteoporosis, ricketts and calcium depletion in females associated with pregnancy.
Preferably, the medicament is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of calcium depletion in bone.
The suitable dosage range for nabumetone depends on the nature of the calcium depletion and on the condition of the patient. It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.
Nabumetone may be formulated for administration by any route, and examples are oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of nabumetone.
The medicaments may, for example, be in the form of tablets, dispersible tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The medicaments, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycerine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.
Solid medicaments may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute nabumetone throughout those medicaments employing large quantities of fillers. When the medicament is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The medicament may also be in the form of an ingestible capsule, for example of gelatin containing nabumetone if desired with a carrier or other excipients.
Medicaments for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid medicaments may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
Nabumetone may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the medicaments may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, an i-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation.
As mentioned hereinbefore, the effective dose of nabumetone depends on the nature of the calcium depletion in the bone, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 2000 mg of nabumetone and preferably will contain from 30 to 1000 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 750, 800 or 1000 mg. The composition may be administered once or more times a day for example 2, 3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of nabumetone and be administered in multiples, if desired, to give the preceding daily dose.
Most preferably nabumetone compositions are in the form of 500 mg swallow tablets.
The present invention further provides a pharmaceutical composition for use in the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier. Such compositions may be prepared in the manner as hereinbefore described.
The efficacy of nabumetone in treating calcium depletion in bone is illustrated by the following clinical study.
Clinical Data
Nine patients (3 males and 6 females) aged 48.2 years in average (range 25-66) , with baseline values of urinary calcium excretion above the normal range, were treated with nabumetone, lg/daily orally for 2 weeks. Nabumetone reduced urine calcium excretion in all subjects. The average reduction was 31%: from 365.8 mg/24 hrs. to 252 mg/24 hrs. (baseline and after 2 weeks respectively) .
The change was statistically significant (P<0.005). Urinary exeretion of hydroxyproline was reduced in 8 out of 9 patents (5 had baseline values above the normal range) .
The average reduction was 31.8%: from 25.7 mg/ml/hr. to 17.5 mg/ml/hr. (P<0.05).
Conclusion
This study suggests that nabumetone may be able to reduce the amount of bone resorption in patents with IH and may have a prophylactic role in hypercalciuric patients with high bone turnover who are candidates for developing osteoporosis.

Claims

Claims
1. The use of nabumetone in the manufacture of a medicament for the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone.
2. The use of nabumetone according to claim 1 wherein the disorder is osteoporosis.
3. The use of nabumetone according to claim 1 wherein the disorder is ricketts.
4. The use of nabumetone according to claim 1 wherein the disorder is calcium depletion in females associated with pregnancy.
5. A use according to any one of.claims 1 to 4 wherein the medicament is adapted for oral administration.
6. A use according to any one of claims 1 to 4 wherein the medicament is adapted for parenteral administration.
7. A use according to any one of claims 1 to 4 wherein the medicament is adapted for topical administration.
8. A use according to any one of claims 1 to 4 wherein the unit dose medicament is in the range of 20 to 2000 mg.
9. A use according to any one of claims 1 to 4 wherein the unit dose of medicament is in the form of a swallow tablet containing 500 mg of nabumetone.
10. A method for the prophylaxis and/or treatment of disorders associated with calcium depletion in the bone in human or non-human animals, which comprises administering an effective, non-toxic amount of nabumetone to a sufferer in need thereof.
5 11. A method according to claim 10, for the prophylaxis and/or treatment of osteoporosis in human or non-human animals, which comprises administering an effective, non toxic amount of nabumetone to a sufferer in need thereof.
10 12. A method according to claim 10, for the prophylaxis and/or treatment of ricketts in human or non-human animals, which comprises administering an effective, non toxic amount of nabumetone to a sufferer in need thereof.
1513. A method according to claim 10, for the prophylaxis and/or treatment of calcium depletion in human or non-human females associated with pregnancy, which comprises administering an effective, non toxic amount of nabumetone to a sufferer in need thereof.
20
14. A method according to claim 10 in which the nabumetone composition is adapted for oral administration.
15. A method according to claim 10 in which the nabumetone 25 composition is adapted for parenteral administration.
16. A method according to claim 10 in which the nabumetone composition is adapted for topical administration.
30 17. A method according to claim 10 in which the unit dose of nabumetone is in the range of 20 to 2000 mg.
18. A method according to claim 10 in which the unit dose of nabumetone is in the form of a swallow tablet containing 500 mg of nabumetone.
19. A pharmaceutical composition for use in the prophylaxis and/or treatment of disorders associated with
5 calcium depletion in the bone which comprises an effective amount of nabumetone and a pharmaceutically acceptable carrier.
20. A pharmaceutical composition according to claim 19 for 10 use in the prophylaxis and/or treatment of osteoporosis.
21. A pharmaceutical composition according to claim 19 for use in the prophylaxis and/or treatment of ricketts.
1522. A pharmaceutical composition according to claim 19 for use in the prophylaxis and/or treatment of calcium depletion in females associated with pregnancy.
23. A pharmaceutical composition according to any one of 20 claims 19 to 22 which is adapted for oral administration.
24. A pharmaceutical composition according to any one of claims 19 to 22 which is adapted for parenteral administration.
25
25. A pharmaceutical composition according to any one of claims 19 to 22 which is adapted for topical administration.
26. A pharmaceutical composition according to any one of 30 claims 19 to 22 wherein the unit dose of nabumetone is in the range of 20 to 2000 mg.
27. A pharmaceutical composition according to any one of claims 19 to 22 wherein the unit dose of nabumetone is 500
35 mg and the composition is in the form of a swallow tablet.
PCT/EP1991/001750 1990-09-22 1991-09-13 Use of nabumetone against calcium depletion WO1992004892A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909020697A GB9020697D0 (en) 1990-09-22 1990-09-22 Treatment
GB9020697.0 1990-09-22

Publications (1)

Publication Number Publication Date
WO1992004892A1 true WO1992004892A1 (en) 1992-04-02

Family

ID=10682612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001750 WO1992004892A1 (en) 1990-09-22 1991-09-13 Use of nabumetone against calcium depletion

Country Status (5)

Country Link
AU (1) AU8521591A (en)
GB (1) GB9020697D0 (en)
IE (1) IE913315A1 (en)
WO (1) WO1992004892A1 (en)
ZA (1) ZA917520B (en)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Drugs, volume 40, suppl. 5, 1990, P. M]nzel et al.: "Efficacy and safety of nabumetone in 4541 elderly patients from a drug monitoring study", pages 62-64, see the whole article *
La Clinica Therapeutica, volume 133, fasc. 6, no. 812, 30 June 1990, F. Catalano et al.: "Analgesic and anti-inflammatory effect of nabumetone in osteo-articular deseases in the acute phase", pages 379-386, see abstract in english *
Pharmatherapeutica, volume 3, no. 9, 1984, J. Gillgrass et al.: "Nabumethone: a double-blind study in osteoarthrosis", pages 592-594, see the whole article *

Also Published As

Publication number Publication date
ZA917520B (en) 1992-07-29
IE913315A1 (en) 1992-02-25
AU8521591A (en) 1992-04-15
GB9020697D0 (en) 1990-11-07

Similar Documents

Publication Publication Date Title
US5371092A (en) Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
EP0269303B1 (en) Piperidine derivative for treating pain
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
US4322411A (en) Anti-inflammatory nucleosides
US4425363A (en) Treatment of tardive dyskinesia in mammals
US6121291A (en) Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
US5695774A (en) Use of nabumetone or 6-methoxynaphthyl acetic acid for the treatment of dementia
Ramsey-Goldman The effect of pregnancy on the vasculitides
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
WO1996030016A2 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
US20020103250A1 (en) Method of treatment or prophylaxis
WO1992004892A1 (en) Use of nabumetone against calcium depletion
IE51738B1 (en) Deazapurine nucleoside,formulations thereof,and use thereof in therapy
WO1992008452A1 (en) Use of nabumetone for the treatment of myofascial pain syndrome
WO1992008451A1 (en) Use of nabumetone for treatment of cancer pain
JP2816500B2 (en) Anti-osteoporosis agent
JP2002512189A (en) Treatment of general anxiety with paroxetine
MXPA00010343A (en) Treatment of generalized anxiety disorder with paroxetine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载